We focus on proven molecules, new formulations, and indications to lower scientific risks and fulfill unmet needs in important and financially attractive markets.
Aucta operates a hybrid commercialization model, combining direct U.S. marketing with strategic international in and out-licensing. In the U.S., the company has built an in-house commercial organization of professionals with deep CNS expertise, supported by a field sales force and dedicated market access team. This infrastructure enabled the successful launch of Motpoly XRTM in 2024, which achieved rapid prescription growth and strong payer coverage across key segments such as Medicaid and commercial insurance plans.